Purpose. The letrozole study 025 is a large (n = 907), international, double-blind, randomized, phase III trial in postmenopausal women with advanced breast cancer. This subanalysis compares the efficacies of letrozole and tamoxifen as first-line therapy in postmenopausual women with advanced breast cancer according to site of metastatic lesions and Karnofsky Performance Status (KPS).
INTRODUCTION
The third-generation aromatase inhibitors, letrozole (Femara Pfizer; New York, NY), have displaced aminoglutethimide and megestrol acetate as second-line treatments for hormonesensitive, advanced breast cancer in postmenopausal women [1] [2] [3] [4] . This success has encouraged their testing as first-line therapy in phase III clinical trials, where the current standard therapy for the past 20 years has been tamoxifen. Letrozole was shown, in study 025, to be superior to tamoxifen in terms of time to progression (TTP) and overall response rate (ORR) [5, 6] .
Advanced breast cancer presents a range of pathologic conditions and clinical outcomes. Nearly all patients are likely to develop bone metastases, and more than 50% of patients will have some liver involvement [7, 8] . Bone metastases account for a substantial amount of disability, while liver metastases are associated with a higher mortality. To further evaluate the efficacy of letrozole in advanced breast cancer, we performed a subset analysis of study 025 according to whether patients had nonvisceral metastases, visceral metastases without liver involvement, or liver metastases.
Another outcome variable that can be used to evaluate treatment in cancer patients is maintenance of functional ability. For patients with metastatic disease, palliative treatment is usually the only option, and the goal is to keep patients as active and independent for as long as possible. While quality of life (QOL) assessments can provide additional information, a functional assessment such as that of the Karnofsky Performance Status (KPS) scale has widespread use and is highly correlated with overall survival [9, 10] . Using this scale, tamoxifen has been shown to maintain good functional ability for longer than other treatments in advanced breast cancer patients [11] . Here, we present data relating to KPS assessments made during study 025 for the previously mentioned subsets of patients with metastatic disease.
MATERIALS AND METHODS

Study Design
The study followed a randomized, double-blind, double-dummy design and was conducted at 201 centers in 29 countries. Patients were assigned once-daily treatment of either 2.5 mg letrozole or 20 mg tamoxifen, with placebos to match the complementary treatment (double-dummy technique). Patients remained on first-line treatment until progression or discontinuation for any other reason, if recommended by the site investigator. Provided they remained eligible for further endocrine therapy, patients could be switched, at the investigator's discretion, to the alternative treatment on progression. All patients were followed for overall survival.
Eligibility Criteria
The trial was open to postmenopausal women with either metastatic disease or locally advanced disease that was confirmed by histologic or cytologic tests (stage IIIB according to American Joint Committee on Cancer [1992] criteria) and not amenable to treatment by surgery or radiotherapy. Previous chemotherapy (one regimen) for advanced disease was permitted when there was objective evidence that progression had occurred within 3 months before the start of the study. Prior adjuvant endocrine therapy was allowed provided it had been discontinued at least 12 months prior to study entry. A KPS score of at least 50 (World Health Organization grade 0-2) was required. The major exclusion criteria were evidence of central nervous system (CNS) metastasis, bilateral diffuse lymphangitis carcinomatosa of the lung with more that 50% involvement, and metastasis of the liver that exceeded 33% of volume.
Assessment of Efficacy
The primary end point was TTP (defined as the interval between the date of randomization and the earliest date of disease progression). Secondary end points were ORR (taken as the percentage of patients with complete responses [CRs] or partial responses [PRs] , as confirmed by a second evaluation 3 months later), duration of overall response, rate of clinical benefit (CR, PR, or stabilization of disease/no change [NC] , lasting at least 24 weeks), duration of clinical benefit, time to treatment failure (TTF), time to response, and overall survival. Patient assessments that included physical and hematological examinations and a performance status evaluation were made every 3 months.
Statistical Methodology
Median time to event was estimated by the Kaplan-Meier product-limit method. Treatments were compared by Cox 491 Letrozole versus Tamoxifen in Metastatic Subgroups and on KPS proportional hazards regression models (time to event data), testing the influence of baseline covariates on the treatment difference as well as testing the effect of each covariate in the presence of the other covariates. Differences between treatments in discrete data, such as response, clinical benefit, and deteriorating/improving KPS score were compared using logistic regression models. The protocol prospectively planned that these analyses be undertaken.
RESULTS
Patients
Demographic data were fully presented previously [5] and are summarized in Table 1 . Baseline characteristics of the 907 patients in the two study arms were well balanced, with a median age of 64.5 years. Most patients (93%) had metastatic disease. Only 167 (19%) had previously received adjuvant tamoxifen, and the majority of these (126) had stopped adjuvant treatment at least 2 years before enrollment into the study. Soft-tissue disease occurred in only 25%, but soft-tissue lesions were present in 62% of the study population. Bone lesions were dominant (i.e., bone disease only or bone disease plus soft-tissue disease) in 30%, but present in 52%, of patients. Visceral lesions were dominant in 44% of patients (i.e., viscera dominant in the presence of any visceral site regardless of involvement of bone or soft tissue). Baseline KPS scores between 80 and 100 were recorded for 92% of patients [5] . The median follow-up at the cut off date for the updated analysis [6] was approximately 32 months.
Efficacy
The updated results of study 025 [6] confirmed the previously reported results [5] . Median TTP was 9.4 months for letrozole and 6.0 months for tamoxifen, representing an almost 30% lower risk for progression (hazard ratio 0.72; 95% confidence interval [CI] = 0.62-0.83; p < 0.0001) ( Table 2 ) [6] .
In patients without visceral disease, the median TTPs were 10.9 months with letrozole and 6.3 months with Abbreviation: PFR-12 = progression-free rate at 12 months.
Hazard ratio <1 favors letrozole (lower risk for progression).
Mouridsen, Sun, Gershanovich et al. 492 tamoxifen (hazard ratio 0.75; 95% CI = 0.62-0.91; p = 0.004) ( Table 2 , Fig. 1A ). For those with visceral disease without liver involvement (most had lung involvement), the median TTPs were very similar at 11.9 and 6.1 months, respectively (hazard ratio 0.66; 95% CI = 0.51-0.86; p = 0.002) ( Table 2 , Fig. 1B ). In patients with liver metastases, the benefit of letrozole over tamoxifen was smaller, but still significant. The median TTPs for patients with liver metastases were 3.8 months with letrozole and 3.0 months with tamoxifen (hazard ratio 0.64; 95% CI = 0.43-0.94; p = 0.02) ( Table 2 , Fig. 1C ). KPS was relatively insensitive to change in these firstline patients. A worsening of KPS score by 20 points or more occurred in similarly modest numbers of patients in both treatment arms in the subsets of nonvisceral metastases (letrozole 20%, tamoxifen 22%) and liver metastases (letrozole 23%, tamoxifen 24%). In the subset of patients with visceral metastases without liver involvement (mostly lung), significantly fewer letrozole patients (14%) than tamoxifen patients (30%) experienced deteriorations in their KPS scores of 20 points or more ( Table 3 ). In that subset of patients, time to worsening was significantly longer for letrozole than for tamoxifen patients (p = 0.0001), but "delay" has little meaning in view of the modest numbers of patients experiencing deterioration. Generally, median time to worsening was not estimable. Improvement in KPS score by at least 20 points sustained for at least 6 months occurred in very modest numbers of patients. In the subset of patients with nonvisceral disease, it was observed in 11% of patients given letrozole and in 8% of patients given tamoxifen. In patients with liver metastases, improvement in KPS score was observed in 6% of patients treated with letrozole and in 7% of patients treated with tamoxifen. In patients with visceral metastases without liver involvement, improvement in KPS score occurred in 20% of those treated with letrozole compared with 9% of those treated with tamoxifen (p = 0.06) ( Table 3) .
Overall Survival
The final overall survival analysis of study 025 (median follow-up period of 32 months) has been reported [6] . The median overall survival time was slightly longer in the letrozole arm (34 months) than in the tamoxifen arm (30 months). Although this difference in overall survival was not statistically significant (by the protocol-specified overall log-rank test), there was a significant early survival benefit for patients in the letrozole arm over the first 2 years of the study. In the subset of patients with nonvisceral metastases, 54% in each treatment arm switched treatments on progression. The median survival time in both treatment arms was 3 years. In the subset of patients with visceral metastases without liver involvement, 49% in each treatment arm crossed over. The median overall survival times were 34 months for letrozole and 31 months for tamoxifen. In the subset of patients with liver metastases, 51% in the 
-13.6) for letrozole (n = 258) and 6.3 months (95% CI = 5.8-9.0) for tamoxifen (n = 246). B) Patients with visceral metastases without liver involvement: median TTPs were 11.9 months (95% CI = 8.6-14.7) for letrozole (n = 135) and 6.1 (95% CI = 4.6-9.0) for tamoxifen (n = 153). C) Patients with liver metastases: median TTPs were 3.8 months (95% CI = 3.1-6.1) for letrozole (n = 60) and 3.0 months (95% CI = 3.0-3.2 months) for tamoxifen (n = 55).
letrozole arm were able to switch to tamoxifen on progression, compared with only 36% in the tamoxifen arm switching to letrozole on progression. The median overall survival times were 19 months for patients initially randomized to letrozole and 11.5 months for patients initially allocated to the tamoxifen arm (p = 0.07, data not shown).
Safety
The safety analysis of the two monotherapies included a total of 910 patients (455 in each arm). Although at least one adverse event (including worsening of tumor-related symptoms) was reported in most patients [5] , there were differences among subgroups in the nature of adverse events reported. In the subset of patients without visceral metastases (i.e., with bone and/or soft-tissue disease), the five most frequent complaints were: bone pain, back pain, hot flushes, nausea, and arthralgia in both treatment arms (Table 4 ). In the subset of patients with visceral metastases without liver involvement (i.e., mainly lung), the five most frequently reported adverse events were: dyspnea, cough, arthralgia, back pain, and hot flushes. In the tamoxifen arm, nausea was the third most frequently reported adverse event (Table 4 ). In the subset of patients with liver metastases (several of whom also had lung involvement), the five most common adverse events were: bone pain, nausea, hot flushes, dyspnea, and arthralgia for patients treated with letrozole but bone pain, fatigue, back pain, nausea, and constipation and dyspnea (equally often) with tamoxifen ( Table 4) .
The frequencies and nature of reported adverse events suspected to be related to the study drug were similar for the letrozole and tamoxifen treatment arms [5] . An overall 7% of patients discontinued the study due to adverse events, withdrawal of consent, or death. Progression of disease was associated with discontinuations due to adverse events [5] and, for this reason, it is difficult to distinguish discontinuations primarily due to adverse events. It is estimated that 2%-3% of patients in each treatment arm discontinued first-line treatment primarily because of adverse events.
DISCUSSION
The present data build on the already published results of study 025 and demonstrate the superiority of the aromatase inhibitor letrozole over tamoxifen in the first-line treatment of advanced breast cancer in postmenopausal women.
• Letrozole resulted in a significantly longer TTP compared with tamoxifen in all subgroups of patients with metastatic lesions.
• Patients with nonvisceral or visceral, but not liver, metastases had longer TTPs than patients with liver lesions. In patients with nonvisceral metastases, the Hazard ratio <1 favors letrozole (lower risk of worsening).
Odds ratio for worsened KPS score <1 favors letrozole (lower odds of worsening).
Odds ratio for improved KPS score >1 favors letrozole (higher odds of improvement).
Worsened = deterioration of 20 points or more at any time.
Improved = improvement of 20 points (or more) sustained for at least 6 months, in patients with an initial KPS score ≤80.
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• TTP was shortest for patients with liver lesions. Letrozole afforded a significant benefit over tamoxifen.
• Although the time to worsening of KPS was significantly longer with letrozole than with tamoxifen, KPS was relatively insensitive to change in this population receiving first-line endocrine therapy. While deterioration of at least 20 points in KPS score occurred in 20%-22% of patients with nonvisceral metastases, similar results occurred in patients with liver metastases (23%-24%), although progression occurred much earlier in the latter patients. In patients with mainly lung metastases (visceral without liver involvement), deterioration in KPS occurred in twice as many patients with tamoxifen (30%) as with letrozole (14%).
• These results were generally mirrored by improvements of at least 20 points in KPS score sustained for at least 6 months, particularly in the subset of patients with visceral metastases without liver involvement For more than 20 years, tamoxifen has been the standard first-line therapy for hormone-sensitive breast cancer in postmenopausal women. The third-generation aromatase inhibitors have now challenged the position of tamoxifen with favorable outcomes. Anastrozole was demonstrated in two trials to be at least as effective as tamoxifen [12, 13, 14] and, in the present study, letrozole demonstrated superiority to tamoxifen in TTP, TTF, response rate, and early survival, and demonstrated equivalence in overall survival [5, 6] . In addition, the time to worsening of performance status score was longer with letrozole.
The superiority of letrozole over tamoxifen in TTP was apparent irrespective of site of metastasis: nonvisceral, visceral without liver involvement, and liver; however, in patients with liver metastases, TTPs were only approximately 30%-50% of the TTPs in patients without liver metastases.
It is well known that the presence of liver metastases is a predictor of poor survival, and this was supported by the relatively short TTP seen in these patients, as well as a substantially shorter median overall survival. Generally, postmenopausal patients with receptor-positive metastatic disease are offered endocrine therapy as a first-line systemic approach. Those responsive may be offered a secondline endocrine therapy, whereas those nonresponsive are offered chemotherapy as a second-line systemic option. The relatively short TTP with first-line endocrine therapy in patients with liver metastases calls for the evaluation of the optimal sequence of endocrine therapy and chemotherapy.
CONCLUSION
In conclusion, this subanalysis by different sites of metastatic lesion and on KPS score indicates that the efficacy of letrozole as first-line endocrine therapy is superior to that of tamoxifen in patients with nonvisceral metastases, with visceral metastases without liver involvement, and with liver metastases. The reliability of results was established by the primary and final findings of the overall study, and data provided by this subanalysis provide further evidence for the consistently superior effects and significant clinical benefit of first-line letrozole in postmenopausal patients with advanced, hormone-sensitive breast cancer.
